Bradley Campbell, President and COO of Amicus Therapeutics, was recently interviewed for Site Selection Magazine, sharing insight on the Company’s strategic decision to select emerging medical hub, Philadelphia, as choice city and new home of Amicus’ state-of-the-art Global Research and Gene Therapy Center of Excellence.
Investors & Media ❯ Featured Coverage
Click Below to Sort Topics
In an article in Pharmaceutical Executive, Patrik Florencio, Chief Compliance and Risk Officer, and John F. Crowley, Chairman and CEO, shared the concrete action steps Amicus has taken to ensure it acts with integrity and responsibility by building and sustaining a culture of business ethics.
Amicus Chairman and CEO, John Crowley, sat down with renowned podcast host, Tim Ferriss of The Tim Ferriss Show, to talk life, being a father of two children living with Pompe disease, and leading a rare disease biotechnology company towards the forefront of the human genome medicine revolution.
John Crowley was awarded the Healthcare Technology Report #1 ranking of the Top 25 Biotech CEOs of 2020 for his career accomplishments and demonstrated leadership capabilities over a sustained period of time.
“We paid particular attention to CEOs who dedicated themselves to developing deep domain expertise, running organizations of high integrity, and who were mission-driven in solving critical health problems.”
– The Healthcare Technology Report
Amicus Therapeutics wins the UK Prix Galien award for Innovative Product, marking the first time in the history of the awards that an orphan drug received this esteemed recognition.
John Crowley, Chairman and CEO of Amicus Therapeutics, was interviewed by Pompe Disease News sharing his personal experience with Pompe disease, Enzyme Replacement Therapy (ERT), and the optimistic future for the next-generation of ERT and gene therapy.
Amicus Chairman and CEO John Crowley sits down with Entrepreneur Weekly’s Alan Taylor to discuss his personal story with Pompe disease and how he is spearheading an entrepreneurial culture within the biotech industry.
Amicus Therapeutics and Dr. James Wilson with the UPenn Gene Therapy Program are awarded Deal of the Year for their collaboration to advance AAV gene therapy research for rare metabolic disorders.
Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics, is a passionate advocate and expert in a wide variety of issues affecting individuals with rare diseases and their families. She has more than 18 years of experience of strategic marketing, resource development and executive management in nonprofit healthcare and the rare disease patient community.
In the podcast she shares her experiences and perspectives on the impact of patient advocacy for patients and families living with rare diseases.
Globes, the leading financial newspaper in Israel, profiles John Crowley’s personal story and Amicus Therapeutics